Claims for Patent: 7,435,755

Summary for Patent: 7,435,755

Title:	CDDO-compounds and combination therapies thereof
Abstract:	CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.
Inventor(s):	Konopleva; Marina (Houston, TX), Andreeff; Michael (Houston, TX), Sporn; Michael B. (Tunbridge, VT)
Assignee:	The Trustees of Dartmouth College (Hanover, NH) Board of Regents, The University of Texas System (Austin, TX)
Application Number:	09/998,009
Patent Claims:	1. A method for inducing cytotoxicity in a cancer cell comprising contacting said cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent, wherein the CDDO-Me and the chemotherapeutic agent are provided in a combined amount effective to induce cytotoxicity in said cell. 2. The method of claim 1, wherein the CDDO-Me is contacted with said cancer cell prior to contacting said cell with said chemotherapeutic agent. 3. The method of claim 1, wherein said chemotherapeutic agent is contacted with said cell prior to contacting said cell with the CDDO-Me. 4. The method of claim 1, wherein said cancer cell is a leukemic cell. 5. The method of claim 4, wherein said leukemic cell is a blood cancer cell, a myeloid leukemia cell, a monocytic leukemia cell, a myelocytic leukemia cell, a promyelocytic leukemia cell, a myeloblastic leukemia cell, a lymphocytic leukemia cell, an acute myelogenous leukemic cell, a chronic myelogenous leukemic cell, a lymphoblastic leukemia cell, a hairy cell leukemia cell. 6. The method of claim 1, wherein said cancer cell is a solid tumor cell. 7. The method of claim 6, wherein said solid tumor cell is a bladder cancer cell, a breast cancer cell, a lung cancer cell, a colon cancer cell, a prostate cancer cell, a liver cancer cell, a pancreatic cancer cell, a stomach cancer cell, a testicular cancer cell, a brain cancer cell, an ovarian cancer cell, a lymphatic cancer cell, a skin cancer cell, a brain cancer cell, a bone cancer cell, a soft tissue cancer cell. 8. The method of claim 1, wherein said cancer cell is located in a human subject. 9. The method of claim 8, wherein said CDDO-Me is administered locally. 10. The method of claim 9, wherein said CDDO-Me is administered by direct intratumoral injection. 11. The method of claim 9, wherein said CDDO-Me is administered by injection into tumor vasculature. 12. The method of claim 8, wherein said CDDO-Me is administered systemically. 13. The method of claim 12, wherein the CDDO-Me is administered intravenously. 14. The method of claim 12, wherein the CDDO-Me is administered intra-arterially. 15. The method of claim 12, wherein the CDDO-Me is administered intra-peritoneally. 16. The method of claim 12, wherein the CDDO-Me is administered orally. 17. The method of claim 12, wherein the CDDO-Me is administered during ex vivo purging. 18. The method of claim 1, wherein said chemotherapeutic agent is doxorubicin, decitabine, daunorubicin, dactinomycin, mitoxantrone, cisplatin, procarbazine, mitomycin, carboplatin, bleomycin, etoposide, teniposide, mechlroethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, ifosfamide, meiphalan, hexamethylmelamine, thiopeta, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, adriamycin, 5-fluorouracil (5FU), camptothecin, actinomycin-D, hydrogen peroxide , nitrosurea, plicomycin, tamoxifen, taxol, transplatinum, vincristin, vinblastin, TRAIL, dolastatin-10, bryostatin, annamycin, mylotarg, sodium phenylacetate, sodium butyrate, methotrexate, a cortocosteroid or tacrolimus. 19. The method of claim 1, wherein said chemotherapeutic agent is a retinoid. 20. The method of claim 19, wherein said retinoid is selected from the group consisting of all-trans-retinoic acid, 9-cis-retinoic acid, LG100268, LGD1069, fenretinide, and CD437. 21. The method of claim 20, wherein said retinoid is LG100268. 22. The method of claim 1, wherein said cell is contacted with the CDDO-Me a second time. 23. The method of claim 1, wherein said cell is contacted with said chemotherapeutic agent a second time. 24. The method of claim 1, wherein the CDDO-Me and said chemotherapeutic agent are contacted with said cell at the same time. 25. The method of claim 8, further comprising tumor resection. 26. The method of claim 25, wherein said tumor resection occurs prior to said contacting. 27. The method of claim 25, wherein said contacting comprises treating a resected tumor bed with the CDDO-Me and said chemotherapeutic agent. 28. The method of claim 25, wherein said tumor resection occurs after said contacting. 29. The method of claim 25, wherein said contacting occurs both before and after said tumor resection. 30. A method of killing a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to kill said tumor cell. 31. The method of claim 30, wherein said chemotherapeutic agent is a retinoid. 32. A method of inducing apoptosis in a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to induce apoptosis of said tumor cell. 33. The method of claim 32, wherein said chemotherapeutic agent is a retinoid. 34. A method of inducing differentiation in a tumor cell comprising contacting said tumor cell with a 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO)-Me and a chemotherapeutic agent, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to induce the differentiation of said tumor cell. 35. The method of claim 34, wherein said chemotherapeutic agent is a retinoid. 36. A method of treating cancer in a human patient comprising administering 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent to said human patient, wherein said CDDO-Me and said chemotherapeutic agent are provided in a combined amount effective to treat said cancer. 37. The method of claim 36, wherein said chemotherapeutic agent is a retinoid. 38. A method of potentiating the effect of a chemotherapeutic agent on a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and the chemotherapeutic agent. 39. The method of claim 38, wherein said chemotherapeutic agent is a retinoid. 40. A method of inhibiting growth of a tumor cell comprising contacting said tumor cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and a chemotherapeutic agent wherein the CDDO-Me and the chemotherapeutic agent are provided in a combined amount effective to inhibit growth of said tumor cell. 41. The method of claim 40, wherein said chemotherapeutic agent is a retinoid. 42. A method of inducing apoptosis in a lymphoid cell that expresses Bcl-2 comprising contacting said lymphoid cell with 2-cyano-3,12-dioxoolean-1,9-dien-28-methyl ester (CDDO-Me) and an immunosupressive agent. 43. The method of claim 42, wherein the Bcl-2 is endogenous. 44. The method of claim 42, wherein the Bcl-2 is exogenous. 45. The method of claim 44, wherein the Bcl-2 is expressed by a expression vector that comprises a nucleic acid that encodes Bcl-2 under the control of a promoter active in the lymphoid cell. 46. The method of claim 42, wherein the lymphoid cell is a T-cell. 47. The method of claim 42, wherein the lymphoid cell is a cancer cell. 48. The method of claim 42, wherein the lymphoid cell is located in a human. 49. The method of claim 42, where the immunosuppressive agent is a corticosteroid. 50. The method of claim 42, where the immunosuppressive agent is a tacrolimus. 51. The method of claim 42, wherein the lymphoid cell is further contacted with a chemotherapeutic agent.

Details for Patent 7,435,755

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	09/01/2017		2020-11-28